share_log

Acrivon Therapeutics, Inc.'s Quiet Period To End on December 26th (NASDAQ:ACRV)

Acrivon Therapeutics, Inc.'s Quiet Period To End on December 26th (NASDAQ:ACRV)

Acrivon Therapeutics, Inc. 's 的平静期将于12月26日结束(纳斯达克股票代码:ACRV)
Defense World ·  2022/12/19 14:21

Acrivon Therapeutics' (NASDAQ:ACRV – Get Rating) quiet period is set to end on Monday, December 26th. Acrivon Therapeutics had issued 7,550,000 shares in its IPO on November 15th. The total size of the offering was $94,375,000 based on an initial share price of $12.50. During Acrivon Therapeutics' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

阿里冯治疗公司(纳斯达克代码:ACRV-GET Rating)的静默期将于12月26日(星期一)结束。Acrivon治疗公司在11月15日的首次公开募股中发行了7,550,000股票。根据12.50美元的初始股价,此次发行的总规模为94,375,000美元。在阿里冯治疗公司的静默期内,由于美国证券交易委员会的监管规定,参与首次公开募股的内部人士和承销商被限制发布任何研究报告或对公司的收益预期。在该公司的静默期结束后,作为承销商的券商可能会启动对该公司的研究报道。

Analyst Upgrades and Downgrades

分析师升级和下调评级

Several research analysts have issued reports on the stock. Cowen assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued an "outperform" rating on the stock. Piper Sandler assumed coverage on shares of Acrivon Therapeutics in a research report on Sunday, December 11th. They issued an "overweight" rating and a $25.00 price target on the stock. Cowen assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued an "outperform" rating on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued a "buy" rating and a $17.00 price target on the stock.

几位研究分析师已经发布了关于该股的报告。考恩在12月12日星期一的一份研究报告中对Acrivon Treeutics的股票进行了报道。他们对该股给予了“跑赢大盘”的评级。派珀·桑德勒在12月11日周日的一份研究报告中对Acrivon Treeutics的股票进行了报道。他们对该股给予了“增持”评级和25.00美元的目标价。考恩在12月12日星期一的一份研究报告中对Acrivon Treeutics的股票进行了报道。他们对该股给予了“跑赢大盘”的评级。最后,杰富瑞金融集团在12月12日星期一的一份研究报告中对Acrivon治疗公司的股票进行了报道。他们对该股给予了“买入”评级和17.00美元的目标价。

Get
到达
Acrivon Therapeutics
阿克瑞丰治疗公司
alerts:
警报:

Acrivon Therapeutics Price Performance

Acrivon治疗药物性价比

Acrivon Therapeutics stock opened at $11.99 on Monday. Acrivon Therapeutics has a 52 week low of $10.90 and a 52 week high of $20.70.

Acrivon治疗公司的股票周一开盘报11.99美元。Acrivon Treeutics的52周低点为10.90美元,52周高点为20.70美元。

Insider Activity

内幕活动

In other Acrivon Therapeutics news, major shareholder Ltd Chione purchased 400,000 shares of the stock in a transaction dated Thursday, November 17th. The shares were acquired at an average price of $12.50 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the insider now owns 3,856,597 shares of the company's stock, valued at approximately $48,207,462.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
在Acrivon治疗公司的其他消息中,大股东有限公司Chione在11月17日星期四的交易中购买了40万股票。这些股票是以每股12.50美元的平均价格收购的,总交易额为5,000,000.00美元。收购完成后,这位内部人士现在拥有该公司3856,597股股票,价值约48,207,462.50美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过以下方式获取
. In other Acrivon Therapeutics news, major shareholder Ltd Chione bought 400,000 shares of the company's stock in a transaction dated Thursday, November 17th. The shares were bought at an average price of $12.50 per share, for a total transaction of $5,000,000.00. Following the acquisition, the insider now directly owns 3,856,597 shares of the company's stock, valued at $48,207,462.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at
。在Acrivon治疗公司的其他消息中,大股东有限公司Chione在11月17日星期四的一笔交易中购买了40万股公司股票。这些股票是以每股12.50美元的平均价格购买的,总交易金额为5,000,000.00美元。收购完成后,这位内部人士现在直接持有该公司3856,597股股票,价值48,207,462.50美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可在
. Also, Director Ra Capital Management, L.P. purchased 3,389,500 shares of the firm's stock in a transaction that occurred on Thursday, November 17th. The shares were bought at an average price of $12.50 per share, with a total value of $42,368,750.00. Following the completion of the acquisition, the director now owns 4,384,206 shares of the company's stock, valued at approximately $54,802,575. The disclosure for this purchase can be found
。此外,董事在11月17日(星期四)的一次交易中购买了3389,500股该公司的股票。这些股票是以每股12.50美元的平均价格购买的,总价值为42,368,750.00美元。收购完成后,董事现在拥有该公司4,384,206股票,价值约54,802,575美元。关于这次购买的披露可以找到
.
.

About Acrivon Therapeutics

关于Acrivon治疗公司

(Get Rating)

(获取评级)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).

Acrivon治疗公司是一家临床阶段的生物制药公司,该公司致力于开发精确肿瘤学药物,通过利用其基于蛋白质组学的患者响应者识别平台Acrivon Predictive Precision Protetics(AP3),将其与预测其肿瘤对特定药物敏感的患者相匹配。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
  • Is it Time to Take a Bite into Domino's Pizza?
  • MarketBeat: Week in Review 12/12 – 12/16
  • Which Two Bluechip Tech Companies Have Raised Their Guidance?
  • Should You Worry About Elon Musk Selling His Tesla Shares?
  • Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
  • 免费获取StockNews.com关于Acrivon治疗公司(ACRV)的研究报告
  • 是时候去Domino‘s Pizza尝一口了吗?
  • MarketBeat:回顾一周12/12-12/16
  • 哪两家蓝筹科技公司提高了他们的指引?
  • 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗?
  • 拖拉机库存能否突破杯柄收购点?

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

获得Acrivon治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acrivon Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发